A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

Inclusion Criteria:

- Informed consent obtained before any trial-related activities. Trial-related
activities are any procedures that are carried out as part of the trial, including
activities to determine suitability for the trial

- Ongoing participation in pathfinder™2

- Male, age at least 12 years at the time of signing informed consent (in certain
countries the lower age limit will be 18 years, according to local requirements)

Exclusion Criteria:

- FVIII inhibitors (≥0.6 BU) at last visit in pathfinder™2 prior to entry in
pathfinder™7

- Planned surgery during the trial

- Major surgery performed within 4 weeks prior to screening

- Previous participation in this trial. Participation is defined as signed informed
consent

- Any disorder, except for conditions associated with haemophilia A, which in the
investigator's opinion might jeopardise patient's safety or compliance with the
protocol